[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369613-105":59,"doc-detail-369613-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","hmgb1-boxa-gene-therapy-in-reversing-cisplatin-resistance-in-non-small-cell-lung-cancer","HMGB1-BoxA gene therapy in reversing cisplatin resistance in non-small cell lung cancer","","Cisplatin is widely used for non-small cell lung cancer, yet clinical benefit is constrained by acquired drug resistance. The study evaluates whether HMGB1-BoxA gene therapy (BoxA) can reverse cisplatin resistance in A549/Cis-R and H460/Cis-R cells. BoxA markedly suppresses growth capacity, lowering cell viability, colony formation, cancer stemness, and self-renewal. Treatment also increases cisplatin sensitivity and promotes apoptosis in cisplatin-treated resistant cells, while reducing cytoplasmic HMGB1 localization to disrupt resistance mechanisms.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/hmgb1-boxa-gene-therapy-in-reversing-cisplatin-resistance-in-non-small-cell-lung-cancer/369613/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/hmgb1-boxa-gene-therapy-in-reversing-cisplatin-resistance-in-non-small-cell-lung-cancer/369613.png","ImageObject",300,407,{"name":92,"@type":93},"Bintang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the research address in non-small cell lung cancer treatment?","Question",{"text":112,"@type":113},"It addresses the limited effectiveness of cisplatin caused by the development of acquired drug resistance in patients with NSCLC.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which cell models were used to test HMGB1-BoxA gene therapy?",{"text":117,"@type":113},"The study investigated two NSCLC cisplatin-resistant cell lines: A549/Cis-R and H460/Cis-R.",{"name":119,"@type":110,"acceptedAnswer":120},"How does BoxA affect resistant cells and cisplatin response?",{"text":121,"@type":113},"BoxA significantly impairs growth capacity, reduces viability and colony formation, lowers cancer stemness and self-renewal, enhances cisplatin sensitivity, and promotes apoptosis in cisplatin-treated resistant cells.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369613,1790301006,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962085564381,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","OPEN ACCESS  \nCitation: Puthdee N, Mai V-H, Settayanon S, Chanvorachote P, Aporntewan C, Mutirangura A, et al. (2025) HMGB1-BoxA gene therapy in reversing cisplatin resistance in non-small cell lung cancer. PLoS One 20(6): e0327144 .  \n[https://doi.org/10.1371/journal.pone.0327144](https://doi.org/10.1371/journal.pone.0327144)[ ](https://doi.org/10.1371/journal.pone.0327144)[Editor:](Editor: Vino Cheriyan)[ Vino Cheriyan](Editor: Vino Cheriyan), IHRC, Inc. (Human Resource Service Administration), UNITED STATES OF AMERICA  \nReceived: March 19, 2025  \nAccepted: June 10, 2025  \nPublished: June 25, 2025  \nPeer Review History: PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: [https://doi.org/10.1371/journal](https://doi.org/10.1371/journal). pone.0327144  \nCopyright: © 2025 Puthdee et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution,  \nRESEARCH ARTICLE  \nHMGB1-BoxA gene therapy in reversing cisplatin resistance in non-small cell lung cancer  \nNattapong Puthdee1, Van-Hieu Mai2,3, Sirapat Settayanon4,5, Pithi Chanvorachote6, Chatchawit Aporntewan7, Apiwat Mutirangura5, Chanida Vinayanuwattikun8*  \n1 C2F-Postdoctoral Fellowship, Chulalongkorn University, Bangkok, Thailand, 2 Faculty of Medicine, University of Health Sciences, Vietnam National University Ho Chi Minh City, Vietnam, 3 Graduate Program in Clinical Sciences, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand,  \n4 Interdisciplinary Program of Biomedical Sciences, Graduate School, Chulalongkorn University, Bangkok, Thailand, 5 Center of Excellence in Molecular Genetics of Cancer and Human Diseases, Department of Anatomy, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand, 6 Cell-Based Drug and Health Product Development Research Unit and Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand, 7 Department of Mathematics and Computer Sciences & Omics Sciences and Bioinformatics Center, Faculty of Science, Chulalongkorn University, Bangkok, Thailand, 8 Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and The King Chulalongkorn Memorial Hospital, Bangkok, Thailand  \n* [Chanida.vi@chula.ac.th](Chanida.vi@chula.ac.th)  \nAbstract  \nCisplatin is a widely used chemotherapy agent in the treatment of non-small cell lung cancer (NSCLC) . However, its clinical efficacy is limited by the development of drug resistance in patients with NSCLC. Recently, we demonstrated that HMGB1-BoxA gene therapy (BoxA) is an ideal cancer treatment that revitalizes normal cells while promoting cancer cells’DNA break cascade. Increasing cytoplasmic HMGB1 is a reason for cisplatin resistance (Cis-R); in this study, we investigated the potential of BoxA to reverse acquired cisplatin resistance in two NSCLC cell lines, A549/ Cis-R, and H460/Cis-R. The growth capacity of these cancer cells was significantly impaired upon BoxA treatment, resulting in a notable reduction in cell viability, colony formation, cancer stemness, and self-renewal capacity. Significantly, BoxA enhanced cisplatin sensitivity and promoted apoptosis in cisplatin-treated Cis-R cells. Furthermore, BoxA altered the subcellular localization of the HMGB1 protein, decreasing its cytoplasmic localization. BoxA can potentially reverse cisplatin resistance by altering the translocation of HMGB1 .  \nIntroduction  \nNon-small cell lung cancer (NSCLC) is a malignant epithelial neoplasm that counts 80–85% of the lung cancer cases [ 1 ,2] . Despite advances in precision medicine, platinum-based chemotherapy is still an upfront or subsequent standard treatment in advanced disease [3] . The developme","cbCaisrfUq7EkkfI","https://ap.wps.com/l/cbCaisrfUq7EkkfI","pdf",975763,11,"English","# Abstract\n# Introduction\n## Cisplatin resistance in NSCLC\n## Role of HMGB1 and subcellular localization\n# HMGB1 BoxA gene therapy approach","[{\"question\":\"What problem does the research address in non-small cell lung cancer treatment?\",\"answer\":\"It addresses the limited effectiveness of cisplatin caused by the development of acquired drug resistance in patients with NSCLC.\"},{\"question\":\"Which cell models were used to test HMGB1-BoxA gene therapy?\",\"answer\":\"The study investigated two NSCLC cisplatin-resistant cell lines: A549/Cis-R and H460/Cis-R.\"},{\"question\":\"How does BoxA affect resistant cells and cisplatin response?\",\"answer\":\"BoxA significantly impairs growth capacity, reduces viability and colony formation, lowers cancer stemness and self-renewal, enhances cisplatin sensitivity, and promotes apoptosis in cisplatin-treated resistant cells.\"}]","HMGB1-BoxA gene therapy in reversing cisplatin resistance in non-small cell lung cancer | PDF",1790183681,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cfdf7ec87304617c2bdad5b3d474d982.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2d48410c2520f7385c3b48c994c8d46b.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/36ad9b5773aefc2d7e5b6124ef6fb4d0.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5ef6421867629b92b737a64733d329a8.webp",980,1268]